Bryan J Krajicek1, Jay H Ryu1, Thomas E Hartman2, Val J Lowe2, Robert Vassallo3. 1. Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN. 2. Department of Radiology, Mayo Clinic, Rochester, MN. 3. Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN. Electronic address: vassallo.robert@mayo.edu.
Abstract
BACKGROUND: Pulmonary Langerhans cell histiocytosis (PLCH) is an inflammatory lung disease strongly associated with cigarette smoking and an increased risk of malignant neoplasms. Although the chest CT scan characteristics of PLCH are well recognized, the PET scan characteristics of adults with PLCH are unknown. METHODS: We identified 11 patients with PLCH who underwent PET scanning over a 6-year period from July 2001 to June 2007. The presenting clinicoradiologic features including PET scan and chest CT scan findings were analyzed. RESULTS: Five of 11 patients had positive PET scan findings. Of the five PET scan-positive patients, 4 (80%) were women, 4 (80%) were current smokers, and the median age was 45 years (age range, 31 to 52 years). PET scan-positive findings were more likely to be present if the scan was performed early in the clinical course. Three PET scan-positive patients (60%) had multiorgan involvement. PET scan-positive patients had predominantly nodular inflammatory lung disease (> 100 nodules) with most nodules measuring < 8 mm, whereas all PET scan-negative patients had predominantly cystic lung disease with fewer nodules (< 25 nodules). Notable abnormal PET scan findings included foci of increased uptake in nodular lung lesions, thick-walled cysts, bone, and liver lesions. The mean maximum standardized uptake value of the PET scan-positive lesions ranged from 2.0 to 18.2. CONCLUSIONS: PLCH may be associated with abnormal thoracic and extrathoracic PET scan results. Patients with nodular disease seen on chest CT scans appear more likely to have abnormal PET scan findings. Our results suggest that PET scan imaging cannot reliably distinguish between the benign inflammatory nodular lesions of PLCH and malignant lesions.
BACKGROUND: Pulmonary Langerhans cell histiocytosis (PLCH) is an inflammatory lung disease strongly associated with cigarette smoking and an increased risk of malignant neoplasms. Although the chest CT scan characteristics of PLCH are well recognized, the PET scan characteristics of adults with PLCH are unknown. METHODS: We identified 11 patients with PLCH who underwent PET scanning over a 6-year period from July 2001 to June 2007. The presenting clinicoradiologic features including PET scan and chest CT scan findings were analyzed. RESULTS: Five of 11 patients had positive PET scan findings. Of the five PET scan-positive patients, 4 (80%) were women, 4 (80%) were current smokers, and the median age was 45 years (age range, 31 to 52 years). PET scan-positive findings were more likely to be present if the scan was performed early in the clinical course. Three PET scan-positive patients (60%) had multiorgan involvement. PET scan-positive patients had predominantly nodular inflammatory lung disease (> 100 nodules) with most nodules measuring < 8 mm, whereas all PET scan-negative patients had predominantly cystic lung disease with fewer nodules (< 25 nodules). Notable abnormal PET scan findings included foci of increased uptake in nodular lung lesions, thick-walled cysts, bone, and liver lesions. The mean maximum standardized uptake value of the PET scan-positive lesions ranged from 2.0 to 18.2. CONCLUSIONS: PLCH may be associated with abnormal thoracic and extrathoracic PET scan results. Patients with nodular disease seen on chest CT scans appear more likely to have abnormal PET scan findings. Our results suggest that PET scan imaging cannot reliably distinguish between the benign inflammatory nodular lesions of PLCH and malignant lesions.
Authors: Nishant Gupta; Robert Vassallo; Kathryn A Wikenheiser-Brokamp; Francis X McCormack Journal: Am J Respir Crit Care Med Date: 2015-06-15 Impact factor: 21.405
Authors: Wolfgang Peter Mueller; Henriette Ingrid Melzer; Irene Schmid; Eva Coppenrath; Peter Bartenstein; Thomas Pfluger Journal: Eur J Nucl Med Mol Imaging Date: 2012-10-25 Impact factor: 9.236